Howard Berman Discusses Potential Indications for Coya 302

PE: Regarding the other intended indications for Coya 302, can you elaborate on any data found from clinical trials focused on these areas?

Berman: Let me go back and sort of lay out the pathophysiology of these diseases, why this treatment may be beneficial, and why it's not centered just around ALS. It turns out that in other conditions such as Parkinson's and Alzheimer's, these regulatory T cells are dysfunctional and the inflammation drives the disease. These are very important biomarkers. So, what we've learned is that by blocking these multiple channels or pathways at the same time, that's the true way to stop or to slow these diseases. Our goal here is to move this forward into these other diseases. We plan on filing an IND in frontotemporal dementia this year. We're also reading out data in Alzheimer's. A trial was run and data was published last year with one of the components of Coya 302. It's the low dose IL2 portion by itself. Remarkably, what we saw, and we didn't anticipate this, was that the patients actually improved their cognition and their blood biomarkers were improved, everything that you would anticipate. We went and showed this to the Gates Foundation and the Alzheimer's Association and they agreed to fund a randomized double blind trial, and that's reading out in the next few months. It's going to be comparing the placebo to the active arm. We're going to take that data and that is going to inform us on strategy and how we're going to potentially partner it or what the next steps will be in that paradigm.